

**EXPRESSION OF CYCLOOXYGENASE-2 IN MALIGNANT
EPITHELIAL TUMORS OF THE URINARY BLADDER;
HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL
STUDY**

**THESIS SUBMITTED IN PARTIAL FULFILLMENT OF
M.D. DEGREE IN PATHOLOGY**

BY

**Diaa Abd El-Kareem Soliman
(M.B.B.Ch.) Tanta university
Master degree in pathology- Cairo university**

SUPERVISORS

**Prof. Dr. AHMED MOHAMED YEHIA EL-HENNAWY
Professor of pathology
Faculty of Medicine-Cairo university**

**Prof. Dr. SAMIA MOHAMED GABAL
Assistant Professor of pathology
Faculty of Medicine-Cairo university**

**D.R. MOSTAFA SAMY SALEM
Lecturer of pathology
Faculty of Medicine- Cairo university**

**Faculty of Medicine
Cairo University
2009**

Acknowledgment

First of all, I would like to thank the **God** who enables us to think, to plan, to design, to implement and to conclude. None can count the pleasing and the favors of the God.

I wish to express my profound gratitude and deep appreciation to **Professor Dr. Ahmed Mohamed-Yehia El-Hennawy**, Professor of Pathology, Faculty of Medicine, Cairo University, for giving me the advantage of working under his supervision, for his faithful guidance and for giving me great help and golden advices for completing this work.

I'm deeply indebted to **Professor Dr. Samia Mohamed Gabal**, Assistant Professor of Pathology, Faculty of Medicine, Cairo University, for her close continuous encouragement, meticulous scientific supervision, all of which left their marks on each and every aspect of this work.

Also, I'm really grateful to **Dr. Mostafa Samy Salem**, Lecturer of Pathology, Faculty of Medicine, Cairo University, for his precious help, effort and for his continuous guidance which was central to the success of this work.

Many thanks to all staff members of Pathology department and to my colleges for their valuable support and help.

I would like to thank my mother, father, brother and my dear wife who exerted true effort in helping me to complete this work.

Abstract

The malignant urothelial tumors of the urinary bladder represent 95% of the malignant tumors of this organ.

Aim of the work: is to evaluate the expression of cyclooxygenase-2 (COX-2) in the precancerous and malignant epithelial tumors of the bladder and its correlation with the different prognostic factors.

Material and methods: this study included 60 bladder carcinoma specimens obtained by radical cystectomy and 5 control bladder specimens from the mucosa away from the tumors.

Results: there was no statistically significant relationship between COX-2 expression and most of the different clinico-pathological factors while there was statistically significant relationship between COX-2 expression and the stage of the tumors.

Conclusion: there was statistically significant relationship between COX-2 expression and the stage of the tumors. Further studies are needed to determine the possibility of considering COX-2 expression in the malignant bladder tumors as a prognostic factor.

Key words: Urinary bladder, malignant epithelial tumors, COX-2, and prognostic factors.

Contents

LIST OF TABLES	5
LIST OF FIGURES	7
LIST OF GRAPHS	9
LIST OF ABBREVIATIONS	10
INTRODUCTION	11
AIM OF THE WORK	13
REVIEW OF LITERATURE	
- Tumors of the urinary bladder	14
- Benign urothelial tumors of the urinary bladder	18
- Malignant epithelial tumors of the urinary bladder.....	22
- Prognostic factors	57
- Cyclooxygenase-2 (COX-2)	60
MATERIAL AND METHODS	65
RESULTS	69
DISCUSSION	125
CONCLUSIONS AND RECOMMENDATIONS	133
SUMMARY	134
REFERENCES	138
ARABIC SUMMARY	161

List of tables

Table-1	Sex distribution in urinary bladder carcinoma cases.
Table-2	The site of the studied tumors in the urinary bladder.
Table-3	Number of tumors in each studied case of the urinary bladder carcinoma.
Table-4	The size of the tumor in the studied cases.
Table-5	Histological classification of urinary bladder carcinoma in the studied cases.
Table-6	Histological variants of invasive urothelial carcinoma cases.
Table-7	Distribution of bilharziasis in different types of urinary bladder carcinomas.
Table-8	Bilharzial and non-bilharzial urinary bladder carcinoma cases in relation to the patient's mean age.
Table-9	Histological grades of the urothelial carcinoma cases.
Table-10	Histological grades of squamous cell carcinoma cases.
Table-11	Depth of invasion of the tumors in the studied cases.
Table-12	Grading of the urothelial carcinoma cases in relation to the depth of the invasion of the tumor (T).
Table-13	Grading of the squamous cell carcinoma cases in relation to depth of the invasion of the tumor (T).
Table-14	Distribution of carcinoma in situ (CIS), dysplasia and squamous metaplasia in the studied cases.
Table-15	Vascular invasion in the studied urinary bladder carcinoma cases.

Table-16	Lymph node involvement in the studied urinary bladder carcinoma cases.
Table-17	COX-2 immunoreactivity in different studied cases
Table-18	Correlation of COX-2 immunoreactivity to the site of tumor in the urinary bladder.
Table-19	Correlation between COX-2 immunoreactivity and number of tumors in each case of the bladder carcinoma
Table-20	Correlation of COX-2 immunoreactivity to the size of the studied cases.
Table-21	Correlation between COX-2 immunoreactivity and association of different types of bladder carcinoma with bilharziasis.
Table-22	Correlation between COX-2 expression and association of urinary bladder carcinomas with CIS, dysplasia and squamous metaplasia.
Table-23	Correlation of COX-2 expression to carcinoma in situ, dysplasia and squamous metaplasia areas.
Table-24	Correlation of COX-2 immunoreactivity to the depth of invasion of the invasive urothelial carcinoma cases
Table-25	Correlation of COX-2 immunoreactivity to the histological grade of the urothelial carcinoma cases.
Table-26	Correlation of COX-2 immunoreactivity to the lymph node involvement in the different urinary bladder carcinomas
Table-27	Correlation of COX-2 immunoreactivity to the depth of invasion of the squamous cell carcinoma cases.
Table-28	Correlation of the COX-2 immunoreactivity to the histological grade of squamous cell carcinoma cases.

List of figures

Figure-1	Squamous metaplasia of the urothelium associated with bilharziasis (H&E x100).
Figure-2	Immunohistochemical study of the same case showed –ve COX-2 expression in area of squamous metaplasia and in the normal urothelium while some stromal cells were +ve for COX-2 staining (Immunoperoxidase x100).
Figure-3	Focus of carcinoma in situ in a case of invasive urothelial carcinoma (H&E x200).
Figure-4	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x200).
Figure-5	Invasive urothelial carcinoma, low grade (H&E x100).
Figure-6	Immunohistochemical study of the same case showed –ve COX-2 staining (Immunoperoxidase x100).
Figure-7	Invasive urothelial carcinoma, high grade (H&E x100).
Figure-8	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-9	Invasive urothelial carcinoma, high grade (H&E x100).
Figure-10	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-11	Invasive urothelial carcinoma showing a focus of glandular differentiation (H&E).
Figure-12	Immunohistochemical study of the same case showed +ve COX-2 staining with weak intensity (Immunoperoxidase x100).
Figure-13	Focus of lymphoepithelioma-like variant of invasive urothelial carcinoma (H&E x200).
Figure-14	Sarcomatoid variant of invasive urothelial carcinoma showing osseous metaplasia and invading the muscularis propria (H&E x100).
Figure-15	Sarcomatoid variant of invasive urothelial carcinoma (H&E x100).
Figure-16	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).

Figure- 17	Invasive urothelial carcinoma showing vascular invasion (H&E x100).
Figure-18	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-19	Lymph node showing metastatic deposits of urothelial carcinoma (H&E x100).
Figure-20	Immunohistochemical study of the same lymph node showed +ve COX-2 staining with strong intensity (Immunoperoxidase x200).
Figure-21	Squamous cell carcinoma of the bladder, grade-1 (H&E x100).
Figure-22	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x400).
Figure-23	Squamous cell carcinoma of the bladder, grade-2 (H&E x100).
Figure-24	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-25	Squamous cell carcinoma of the bladder, grade-2 (H&Ex100).
Figure-26	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x200).
Figure-27	Squamous cell carcinoma of the bladder, grade-3 (H&E x100).
Figure-28	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-29	Squamous cell carcinoma of the bladder showing vascular invasion (H&E x100).
Figure-30	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).
Figure-31	Adenocarcinoma of the bladder with mucoid activity (H&E x100).
Figure-32	Immunohistochemical study of the same case showed +ve COX-2 staining with moderate intensity (Immunoperoxidase x100).

List of graphs

Graph-1	Histological classification of the studied urinary bladder carcinoma cases.
Graph-2	Vascular invasion in the studied urinary bladder carcinoma cases.

List of abbreviations

A.A.	Arachidonic acid
A. fangchi	Aristolochia fangchi
CAP	College of American Pathologists
CIS	Carcinoma in situ
COX-2	Cyclooxygenase-2
CYT 1A2	Cytochrome P450 1A2
DAB	Di-Amino-Bezidinetetrahydrochloride
H&E	Haematoxylin and Eosin
ISUP	International Society of Urological Pathology
IUC	Invasive urothelial carcinoma
NAT2	N- acetyltransferase-2
NCI	National Cancer Institute
NSAIDs	Non-steroidal Anti-inflammatory Drugs
PUNLMP	Papillary urothelial neoplasm of low malignant potential
PBS	Phosphate-Buffered Saline
P Value	Probability value
Sq C C	Squamous cell carcinoma
TCC	Transitional cell carcinoma
TNM	Tumor-Node-Metastasis
WHO	World Health Organization

Introduction

Urinary bladder tumors comprise a heterogeneous group of lesions. About 95% of the bladder tumors are of epithelial origin (D' hallewin et al., 1996, Volante et al., 2001).

Urothelial carcinomas represent approximately 90% of all primary tumors of this organ (Kutarski et al., 1993, Mhaweche et al., 2002). Primary squamous cell carcinomas represent about 5% of the bladder cancers (Frank et al., 2003). In Egypt, the incidence of squamous cell carcinoma of the urinary bladder is increased due to urinary schistosomiasis (Koraitin et al., 1995). The urinary bladder adenocarcinoma constitute approximately 2% of the malignant tumors of this organ (Fukushima et al., 1989). Other malignant epithelial tumors as small cell carcinomas are very rare (Cheng et al., 2000).

The biological behavior of the urinary bladder carcinomas is unpredictable and the morphological methods are often insufficient to predict the clinical outcome of patients with these tumors (Billerey et al., 1999).

This discrepancy in the behavior of these tumors from recurrence to progression has encouraged the research for prognostic markers; one of these markers is cyclooxygenase-2 (Shirhama, 2000).

Cyclooxygenase (COX) exists in two isoforms, COX-1 and COX-2, and catalyzes the conversion of arachidonic acid to prostaglandins (Sulma et al., 1999). Whereas COX-1 is expressed constitutively in most normal tissues and is required for the normal physiological functions, cox-2 usually is not detectable but induced in response to various stimuli such as oncogenes and tumor promoters (Tsutomu et al., 2001).

Cyclooxygenase-2 (COX-2) overexpression was observed in various malignant tumors as well as in urinary bladder carcinoma (Pruthi et al., 2004). Although there is abundant evidence pointing to the role of (COX-2) expression in tumorigenesis, the mechanisms by which (COX-2) expression exerts its effects on tumorigenesis is not clear, but recent studies have shown that COX-2-derived prostaglandins display their effects through cellular apoptosis and steps of metastasis, thus contributing to the prognosis of these patients with bladder cancer (Kim et al., 2002).

In vitro and animal studies demonstrated a decreased incidence and decreased growth of bladder cancer when administrating non-selective and selective COX-2 inhibitors (Mohseni et al., 2004). Moreover, a large case-control study demonstrated an overall decreased risk of bladder cancer in regular users of non-steroidal anti-inflammatory drugs (Castelao et al., 2000).

Aim of the work

- 1- Histopathological study of different types of urinary bladder carcinomas, their variants, grade and stage.
- 2- Evaluation of cyclooxygenase-2 (COX-2) expression in different types of urinary bladder carcinomas and precancerous lesions.
- 3- Correlation between the expression of cyclooxygenase-2 (COX-2) and different prognostic features in different types of urinary bladder carcinomas.

TUMORS OF THE URINARY BLADDER

WHO Histological classification of tumors of the urinary tract (2004):

I- Urothelial tumors

Infiltrating urothelial carcinoma

With squamous differentiation

With glandular differentiation

With trophoblastic differentiation

Nested

Microcystic

Micropapillary

Lymphoepithelioma-like

Lymphoma-like

Plasmacytoid

Sarcomatoid

Giant cell

Undifferentiated

Non infiltrating urothelial neoplasms

Urothelial carcinoma in situ

Non invasive papillary urothelial carcinoma, high grade

Non invasive papillary urothelial carcinoma, low grade

Non invasive papillary urothelial neoplasm of low malignant potential

Urothelial papilloma

Inverted urothelial papilloma

II- Squamous neoplasms

Squamous cell carcinoma

Verrucous carcinoma

Squamous cell papilloma

III- Glandular neoplasms

- Adenocarcinoma

Enteric

Mucinous

Signet ring cell